Recurrent Episodes with Serous Retinal Detachment and Anterior Uveitis in a Patient Using Nivolumab (Anti -PD-1 Antibody) Therapy: A case report and literature review

REFERENCES

• Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors—an overview. Rheumatology. 2019;58(Suppl7):vii7–16. https://doi.org/10.1093/rheumatology/kez418.
   PubMedGoogle Scholar
• Liu X, Wang Z, Zhao C, et al. Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thorac Cancer. Mar 2020;11(3):810–818. doi:10.1111/1759-7714.13327. PMID: 32017399; PMCID: PMC7049480.
   PubMed Web of Science ®Google Scholar
• Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina. 2018 Jun;38(6):1063–1078. doi:10.1097/IAE.0000000000002181. PMID: 29689030.
   PubMed Web of Science ®Google Scholar
• Theillac C, Straub M, Breton AL, Thomas L, Dalle S. Bilateral uveitis and macular edema induced by nivolumab: a case report. BMC Ophthalmol. 2017 Dec 1;17(1):227. doi:10.1186/s12886-017-0611-3. PMID: 29195497; PMCID: PMC5709862.
   PubMedGoogle Scholar
• Miyamoto R, Nakashizuka H, Tanaka K, et al. Bilateral multiple serous retinal detachments after treatment with nivolumab: a case report. BMC Ophthalmol. 2020 Jun 8;20(1):221. doi:10.1186/s12886-020-01495-w. PMID: 32513129; PMCID: PMC7281950.
   PubMed Web of Science ®Google Scholar
• Geng Q, Jiao P, Jin P, Su G, Dong J, Yan B. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules. Curr Pharm Des. 2018 Feb 12;23(39):6033–6041. doi:10.2174/1381612823666171004120152. PMID: 28982322
   Google Scholar
• Parker JS, Feagin W, Wang C, Heersink M, Parker JS. Corneal ulceration associated with Nivolumab use. Am J Ophthalmol Case Rep. 2019;14:26-27. Published 2019 Feb 7. doi:10.1016/j.ajoc.2019.01.013
   Google Scholar
• Losonczy G, Gijs M, Nuijts RMMA. Nivolumab-Induced Ulcerative Keratitis-A Case Report [published online ahead of print, 2020 Aug 19]. Cornea. 2020; 10.1097/ICO.0000000000002460. doi:10.1097/ICO.0000000000002460
   Google Scholar
• Deitch-Harel I MD, Raskin E MD, Habot-Wilner Z MD, Friling R MD, Amer R MD, Kramer M MD. Uveitis Induced by Biological Agents Used in Cancer Therapy [published online ahead of print, 2020 Jun 16]. Ocul Immunol Inflamm. 2020;1-5. doi:10.1080/09273948.2020.1760310
   Google Scholar
• De Velasco G, Bermas B, Choueiri TK. Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol. 2016;68(2):556–557. doi:10.1002/art.39406.
   PubMed Web of Science ®Google Scholar
• Karlin J, Gentzler R, Golen J. Bilateral anterior uveitis associated with nivolumab therapy. Ocul Immunol Inflamm. 2018;26(2):283–285. doi:10.1080/09273948.2016.1215473.
   PubMed Web of Science ®Google Scholar
• Kanno H, Ishida K, Yamada W, et al. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient. J Infect Chemother. 2017;23(11):774–777. doi:10.1016/j.jiac.2017.04.007.
   PubMed Web of Science ®Google Scholar
• Dermarkarian CR, Patel NA, Villegas VM, Harbour JW. Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer. Am J Ophthalmol Case Rep. 2020;18:100691. doi:10.1016/j.ajoc.2020.100691.
   PubMedGoogle Scholar
• Baughman DM, Lee CS, Snydsman BE, Jung HC. Bilateral uveitis and keratitis following nivolumab treatment for metastatic melanoma. Med Case Rep. 2017;3(2):8. doi: 10.21767/2471-8041.100044.
   PubMedGoogle Scholar
• Richardson DR, Ellis B, Mehmi I, Leys M. Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report. Int J Ophthalmol. 2017;10(7):1183–1186. doi:10.18240/ijo.2017.07.28.
   PubMed Web of Science ®Google Scholar
• Reddy M, Chen JJ, Kalevar A, Terribilini R, Agarwal A. Immune retinopathy associated with nivolumab administration for metastatic non-small cell lung cancer. Retin Cases Brief Rep. 2020;14(2):120–126. doi:10.1097/ICB.0000000000000675.
   PubMedGoogle Scholar
• Arai T, Harada K, Usui Y, Irisawa R, Tsuboi R. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol. 2017 Aug;44(8):975–976. doi:10.1111/1346-8138.13612. PMID: 27649838.
   PubMed Web of Science ®Google Scholar
• Obata S, Saishin Y, Teramura K, Ohji M. Vogt-koyanagi-harada disease-like uveitis during nivolumab (anti-PD-1 Antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol. 2019 Feb 8;10(1):67–74. doi:10.1159/000496682. PMID: 31097947; PMCID: PMC6489058.
   PubMed Web of Science ®Google Scholar
• Kemels D, Ten BJC, Jacob J, Schauwvlieghe PP. The role of checkpoint inhibitors in paraneoplastic acute exudative polymorphous vitelliform maculopathy: report of two cases. Retin Cases Brief Rep. 2020. doi:10.1097/ICB.0000000000001040.
   Google Scholar
• Thomas M, Armenti ST, Ayres MB, Demirci H. Uveal effusion after immune checkpoint inhibitor therapy. JAMA Ophthalmol. 2018;136(5):553–556. doi:10.1001/jamaophthalmol.2018.0920.
   PubMed Web of Science ®Google Scholar
• Parikh RA, Chaon BC, Berkenstock MK. Ocular complications of checkpoint inhibitors and immunotherapeutic agents: a case series. Ocul Immunol Inflamm. 2020 Jul 9:1–6. doi:10.1080/09273948.2020.1766082. PMID: 32643982.
   PubMed Web of Science ®Google Scholar
• Sun MM, Levinson RD, Filipowicz A, et al. Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocul Immunol Inflamm. 2020;28(2):217–227. doi:10.1080/09273948.2019.1577978.
   PubMed Web of Science ®Google Scholar
• Elwood KF, Pulido JS, Ghafoori SD, Harper CA, Wong RW. Choroidal neovascularization and chorioretinal atrophy in a patient with melanoma-associated retinopathy after ipilimumab/nivolumab combination therapy. Retin Cases Brief Rep. 2019. doi:10.1097/ICB.0000000000000882.
   Google Scholar
• Chan PY, Hall P, Hay G, Cohen VML, Szlosarek PW. A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity. Pigment Cell Melanoma Res. 2017;30(6):558–562. doi:10.1111/pcmr.12607.
   PubMed Web of Science ®Google Scholar
• Lee JC, Al-Humimat G, Kooner KS. Acute bilateral uveitis, hypotony, and cataracts associated with ipilimumab and nivolumab therapy: optical coherence tomography angiography findings. Case Rep Ophthalmol. 2020;11(3):606–611. doi:10.1159/000509629.
   PubMed Web of Science ®Google Scholar
• L Hefler J, M Bailey L, El Rahi C, C Schefler A, Bernicker EH. Panuveitis in patient on ipilimumab/nivolumab combination for small-cell lung cancer treated with an intravitreal dexamethasone implant. J oncol pharm Pract. 2020:1078155220969792. doi:10.1177/1078155220969792.
   Web of Science ®Google Scholar
• Brouwer NJ, Haanen JBAG, Jager MJ. Development of ocular rosacea following combined ipilimumab and nivolumab treatment for metastatic malignant skin melanoma. Ocul Oncol Pathol. 2017;3(3):188–192. doi:10.1159/000455150.
   PubMed Web of Science ®Google Scholar
• Matsuo T, Yamasaki O. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep. 2017 Mar 31;5(5):694–700. doi:10.1002/ccr3.911. PMID: 28469878; PMCID: PMC5412830.
   PubMed Web of Science ®Google Scholar
• Gonzales JA, Shantha J, Acharya NR. Combination nivolumab- and cabiralizumab-associated acute bilateral anterior and posterior scleritis and anterior uveitis. Am J Ophthalmol Case Rep. 2018;10:117–118. doi:10.1016/j.ajoc.2018.02.005.
   PubMedGoogle Scholar
• Chang CJ, Chen SJ, Hwang DK, Liu CJ. Bilateral anterior uveitis after immunotherapy for malignant melanoma. Taiwan J Ophthalmol. 2018 Jul-Sep;8(3):173–175. doi:10.4103/tjo.tjo_88_17. PMID: 30294532; PMCID: PMC6169330.
   PubMedGoogle Scholar
• Sandhu HS, Kolomeyer AM, Lau MK, et al. Acute exudative paraneoplastic polymorphous vitelliform maculopathy during vemurafenib and pembrolizumab treatment for metastatic melanoma. Retin Cases Brief Rep. 2019;13(2):103–107. doi:10.1097/ICB.0000000000000604. PMID: 28614138; PMCID: PMC5729061.
   PubMedGoogle Scholar
• Scupola A, Abed E, Sammarco MG, et al. Intravitreal dexamethasone implant for acute exudative polymorphous vitelliform maculopathy. Eur J Ophthalmol. Sep-Oct 2014;24(5):803–807. doi:10.5301/ejo.5000477. PMID: 24803155.
   PubMed Web of Science ®Google Scholar